Abstract | RATIONALE AND AIMS: DESIGN: The CSPS.com is a multicenter, randomized, open-label, parallel-group trial. A total of 4000 high-risk patients with noncardioembolic IS will be randomized 8-180 days after onset to receive aspirin or clopidogrel monotherapy, or DAPT with cilostazol and aspirin or clopidogrel for at least one-year. STUDY OUTCOMES: The primary outcome is IS recurrence. Secondary outcomes are composite occurrences of any stroke, death from any cause, myocardial infarction, vascular death, and other vascular events. DISCUSSION: The CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high-risk patients can be improved by using DAPT involving cilostazol.
|
Authors | Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, CSPS.com Study Investigators |
Journal | International journal of stroke : official journal of the International Stroke Society
(Int J Stroke)
Vol. 10
Issue 2
Pg. 253-8
(Feb 2015)
ISSN: 1747-4949 [Electronic] United States |
PMID | 25487817
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd on behalf of World Stroke Organization. |
Chemical References |
- Phosphodiesterase 3 Inhibitors
- Platelet Aggregation Inhibitors
- Tetrazoles
- Clopidogrel
- Cilostazol
- Ticlopidine
- Aspirin
|
Topics |
- Aged
- Aspirin
(administration & dosage)
- Brain Ischemia
(prevention & control)
- Cilostazol
- Clopidogrel
- Drug Therapy, Combination
- Humans
- Phosphodiesterase 3 Inhibitors
(therapeutic use)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Recurrence
- Research Design
- Stroke
(prevention & control)
- Tetrazoles
(therapeutic use)
- Ticlopidine
(administration & dosage, analogs & derivatives)
|